Compare KPTI & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | TELA |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 31.4M |
| IPO Year | 2013 | 2019 |
| Metric | KPTI | TELA |
|---|---|---|
| Price | $0.51 | $0.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $7.25 | $2.08 |
| AVG Volume (30 Days) | ★ 1.6M | 139.6K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | $80,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.98 | $9.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.57 | ★ 15.84 |
| 52 Week Low | $0.31 | $0.50 |
| 52 Week High | $10.99 | $1.51 |
| Indicator | KPTI | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 29.67 | 43.13 |
| Support Level | $0.31 | $0.61 |
| Resistance Level | $2.16 | $0.97 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 50.74 | 11.57 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.